Context: As we mentioned earlier today on LinkedIn, the Landgericht München I (Munich I Regional Court) yesterday (January 8, 2026 ip fray LinkedIn post) granted Regeneron four more preliminary injunctions (PIs).
What’s new: We have obtained the operative parts of all four decisions. The patent-in-suit, EP2364691 (“VEGF antagonist formulations suitable for intravitreal administration”), is the same formulation-plus-purpose-statement patent over which the Munich court already enjoined Formycon last fall (September 29, 2025 ip fray article). The defendants, as shown on a hearing list outside the courtroom yesterday, are Advanz, Celltrion, Hexal, and Stada.
Direct impact: The PIs against Celltrion, Hexal and Stada are limited to the German market, but five companies from the Advanz group are enjoined with respect to the following list of countries: Austria, Belgium, Bulgaria, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden.
Wider ramifications: This is part of Regeneron’s enforcement of its intellectual property rights related to Eylea (September 25, 2025 ip fray article).
Court and counsel
Panel: Presiding Judge Dr. Oliver Schoen (“Schön” in German), Judge Dr. Katalin Tözsér, and Judge Dr. Florian Schweyer.
Regeneron is represented by Hoyng Rohk Monegier (ip fray firm profile; lead counsel: Dr. Christine Kanz), Advanz by Bird & Bird, Hexal (Sandoz) and Stada by Pentarc (ip fray firm profile), and Celltrion by Maiwald.